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Ovarian cancer (OC) is the seventh most common cancer in women worldwide. Standard 
therapeutic treatments involve debulking surgery combined with platinum-based 
chemotherapies. Of the patients with advanced stage cancer that initially respond to 
current treatments 50%-75% relapse. Immunotherapy-based approaches aimed at 
boosting anti-tumor immunity have recently emerged as promising tools to challenge 
tumor progression. Treatments with inhibitors of immune checkpoint molecules have 
shown impressive results in other types of tumors. However, only 15% of checkpoint 
inhibitors evaluated have proven successful in OC due to the immunosuppressive 
environment of the tumor and the transport barriers. This limits the efficacy of the existing 
immunotherapies. Nanotechnology-based delivery systems hold the potential to 
overcome such limitations. Various nanoformulations including polymeric, liposomes, and 
lipid–polymer hybrid nanoparticles have already been proposed to improve the 
biodistribution and targeting-capabilities of drugs against tumor-associated immune cells, 
including dendritic cells and macrophages. In this review, we examine the impact of 
immuno-therapeutic approaches that are currently under consideration for the treatment 
of OC. In this review we also provide a comprehensive analysis of the existing 
nanoparticle-based synthetic strategies, their limitations and advantages over standard 
treatments. Furthermore, we discuss how the strength of the combination of 
nanotechnology with immunotherapy may help to, overcome the current therapeutic 
limitations associated with their individual application and unravel a new paradigm in the 
treatment of this malignancy. 
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Ovarian cancer (OC) ranks as the seventh leading cause of death in women worldwide. 
According to the American Cancer Society 14,070 deaths and approximately 22,240 new 
cases are predicted for 2018 in the United States (Siegel, 2018). Of the patients with 
advanced stage cancer that initially respond to current treatments 50%-75% relapse. The 
asymptomatic nature of early stage ovarian cancer is the main reason for its late 
diagnosis, which normally occurs at a metastatic stage, drastically reducing the chances 
of a successful outcome of the treatment (Das, Bast, & Jr, 2008; Rauh-Hain et al., 2011). 
Despite the continuous improvement in screening methods, OC-associated mortality 
rates remain high due to the absence of routine early detection approaches. The lack of 
specificity of the available tests and the limitations associated to the application of imaging 
techniques further complicate the diagnostic process  (Russell et al., 2017; Sarojini et al., 
2012; Terry et al., 2016). OC comprises five histological subtypes: low-high grade serous, 
mucinous, clear cells, and endometrioid cancer. Serous OC represents the most common 
carcinoma and accounts for more than 50% of all cases. It is associated with specific 
genetic mutations (i.e. BRCA1, BRCA2, MMR, TP53, BARD1, CHEK2, RAD51, and 
PALB2) spanning from single nucleotides polymorphisms to high frequency of somatic 
gene copies or epigenetic features, indicative of defects in homologous recombination 
repair and gene methylations (Ducie et al., 2017; Kaldawy et al., 2016). These subtypes 
metastatize to the same area, within the peritoneal cavity.  
Currently, the treatment of OC includes debulking surgeries, which are meant to excise 
tumor masses, coupled with extensive chemotherapy, radiotherapy or a combination of 
the three depending on the stage and type of the cancer. Recommended first line 
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treatments for OC are platinum-based and taxols drugs (www.nccn.org/guidelines). In 
some cases, after genetic screening, patients may be eligible for monoclonal antibodies 
therapies such as Bevacizumab, which blocks tumoral angiogenesis by inhibiting the 
vascular endothelial growth factor (VEGF) signaling. Other approaches include using 
Olaparib, Rucaparib, and Niraparib, known as inhibitors of the poly(adenosine 
diphosphate [ADP]-ribose) polymerases (PARPs) and involved in DNA repair. The use of 
the latter treatments has been specifically recommended for patients with BRCA genes’ 
mutations (Coward et al., 2015). Table 1 explains the current therapies available for OC 
including standard and targeted chemotherapies. The state-of-the-art nanotherapies 
currently being use or tested in clinical trials are also mentioned.   
The 5-year survival rate for women with advanced stage OC is approximately 40% 
(Timmermans et al., 2018; Torre et al., 2018) but increases if the ovarian tumor has more 
infiltrating T cells (L. Zhang et al., 2003). The lack of a curative therapeutic regime, the 
frequency of relapse, and the mortality levels underlie the effort needed to refine the 
current treatment options and improve patient outcomes. The diversity of physiopathology 
(Nezhat et al., 2015) between OC types and the heterogeneity of cells infiltrating the 
peritoneum calls for the identification of effective approaches to maintain the bioactivity 
of the payload, precisely aim the target, and preferentially accumulate the drug at the site 
of interest while reducing cytotoxicity.  
Nanomedicines are frequently employed as engineered drug delivery systems that 
support the prolonged circulation of drugs, maintain their bioactivity, reduce their side 
effects, and selectively target diseased cells (Blanco et al., 2015). Targeted 
nanomedicines include liposomal nanocarriers (siRNA-EphA2, OSI-211, Myocet) (Eitan 
This article has not been copyedited and formatted. The final version may differ from this version.














et al., 2014; Seiden et al., 2004; H. Shen et al., 2013), polymeric nanoparticles (abraxane, 
CRLX101) (Pham et al., 2015; Srinivasan et al., 2014), and antibody-drug conjugates 
(Howard, Garcia-parra, et al., 2016). Nanotechnology-based strategies for diagnostic 
tools have been also developed to detect biomarkers and genetic mutations (Engelberth 
et al., 2014), as well as to combine nano-enabled therapeutic and diagnostic capabilities, 
giving rise to “nano-theranostics” (Yaari et al., 2016).  
In this review we discuss the potential of cancer immunotherapy, a recently developed 
field that aims at treating cancer patients by re-stimulating their immune system. 
Particular emphasis will be given to its applications and pitfalls in OC. We also review 
how a nanomedicine approach to immunotherapy may overcome the current therapeutic 
limitations of the treatment of OC and unravel a new paradigm in the cure of this 
malignancy. 
 
2. Immunotherapy and cancer 
Cancer immunotherapy aims at stimulating the immune system in order to provide cancer 
prevention and treatment. The first discoveries of the crucial role played by the immune 
regulation in cancer progression have recently led to the 2018 Nobel Prize for Medicine 
and Physiology to Drs. James P. Allison and Tasuku Honjo (www.nobelprize.org). Their 
studies unraveled fundamental mechanisms that govern immune cell (specifically T cells) 
responses to cancer and provided insights to overcome immune system evasion by 
cancer. Since then, the use of immune checkpoint blockade has been widely recognized 
as an effective cancer treatment. In particular, Dr. Allison and his research group have 
been the first to identify the Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) protein, an 
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immune checkpoint receptor expressed on the surface of activated T cells, believed to 
regulate their proliferation. When the CTLA-4 pathway is activated by co-stimulatory 
molecules (CD80, CD86) the result is hindrance of T-cell function, which inhibits the T-
cell strong anti-cancer potential (Leach et al., 1996). Based on these observations, a 
specific antibody was developed to retain CTLA-4 activation and maintain T-cells in an 
activated status (Chambers et al., 1996). Almost simultaneously, in 1992 Honjo’s group 
discovered Programmed Death-ligand 1 (PD-1) which also acts as a T-cell retainer, 
finding an alternative way to defeat the tumor-mediated immune evasion. The insights 
provided by such inspiring scientists have led to many FDA-approved drugs for the 
treatment of various cancers. These drugs span from sipuleucel-T, approved in 2010 to 
target the immune system for the treatment of prostate cancer (Cheever & Higano, 2011), 
to ipilimumab, the first monoclonal antibody against CTLA-4 for metastatic melanoma 
(Lipson & Drake, 2011). By 2018, eight immunotherapies have been FDA-approved for 
the treatment of several cancers (Table 2), including durvalumab (stage 3 lung cancer), 
blinatumomab (acute lymphoblastic leukemia), and nivolumab (used in combination with 
ipilimumab for previously untreated kidney cancers) (https://www.cancer.gov/fda-
approvals).  
Immunotherapeutic approaches include the use of targeted antibodies and vaccines 
against immune checkpoint inhibitors directed towards a specific immune cell population 
(Ventola, 2017). For instance, due to their antigen presenting capabilities, dendritic cells 
(DC) have been used to develop immune vaccines (Sabado et al., 2017). Depending on 
the molecules employed to activate them, DC are able to re-program or launch a cell-
specific cytotoxic response. Conversely, tumor-associated macrophages (TAMs) have 
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been shown to exert different roles in tumor microenvironment development and 
flourishing (Mills et al., 2016). Approaches that target this macrophage population are 
currently being evaluated, especially since the discovery that the blockade of TAMs 
potentiates the immune checkpoint inhibitors’ effect (Ries et al., 2014; Y. Zhu et al., 2014). 
Adoptive T cell therapy  to re-engineer the T-cell populations against tumor initiation is 
another strategy that has been widely validated (Dzhandzhugazyan et al., 2018). The 
Chimeric Antigen Receptor re-engineered T cells (CAR-T) system has been recently 
approved by the FDA for the treatment of patients with leukemia, large B-cell and non-
Hodgkin lymphomas (Zheng et al., 2018). Other focuses involve the use of a different 
immune cell population, the Natural Killer T cells (NKT). NKT cells naturally stimulate the 
innate and adaptive immune system in several ways, such as the release of interferon-
gamma (IFN-γ) to activate the CD8+ T cell population (Mah & Cooper, 2016). They are 
being investigated as potential immunotherapies both as ex-vivo expanded cell vaccines 
and as combinatorial therapies (Nair & Dhodapkar, 2017).  
 
3. Ovarian cancer: a “cold” enemy 
The characterization of the topographic distribution of immune cells within the tumour in 
a panel of 177 human samples with different cancer types has recently led to their 
categorization in inflamed (“hot”), non-inflamed (“cold”) and “immune excluded” patterns 
according to where the cells are positioned  (Kather et al., 2018). Cold tumors are 
malignancies that display a very limited response to immunotherapies compared to other 
cancer types. OC is considered a “cold” tumor (Preston et al., 2011) despite the significant 
association between tumor immunity and ovarian patient outcomes and the strong 
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correlation between the presence of infiltrating lymphocytes in the primary tumor with 
patient survival (L. Zhang et al., 2003). The reasons behind this lack of effectiveness has 
yet to be clarified. A possible explanation, proposed for pancreatic cancer, suggests that 
the difference between hot and cold tumors reflects the way tumor infiltrating immune 
cells are recognized by cancer cells or engage in the tumor. If such, the properties of the 
microenvironment make a tumor hot or cold. Hot tumors are more sensitive to treatments 
that activate the T cell population, as they are considered to be the main drivers of the 
adaptive immune response, against tumor initiation (Haanen, 2017).  
The tumor microenvironment is a complex hub where different cell types interact with 
each other and with the extracellular matrix and it is plausible that other cells, including 
antigen presenting cells (APC), play an active role in downregulating the immune system. 
APC, including the aforementioned DC, are highly responsive to external stimuli and the 
tumor surroundings can negatively affect their physiological behavior. Indeed, it has been 
shown that endoplasmic reticulum stress is also crucial for triggering cancer resistance 
mechanisms by activating the unfolded protein response, which in turn disrupts the 
physiological immune response (Yadav et al., 2014). Specifically, through the constitutive 
activation of the endoplasmic reticulum stress response factor XBP1, DC undergo an 
abnormal lipid accumulation that leads to their ineffective functioning (Cubillos-Ruiz et al., 
2015). While low infiltration of immune cells both inside and outside the tumor is found in 
OC samples, the co-existence of different immune-microenvironments within the same 
patient partly explains the heterogeneity in the response to treatment often observed in 
patients with recurrent disease (Jiménez-Sánchez et al., 2017). 
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Currently there are no FDA-approved immunotherapies for OC, although there are 
several ongoing clinical trials. Of the 98 total clinical trials, 26 have been completed, 40 
are actively recruiting patients, and 9 have been terminated before their planned end due 
to the inefficacy determined by the limitations described in the previous paragraphs 
(https://clinicaltrials.gov). In 2016, Gaillard et al. reported a comprehensive analysis of all 
clinical trials on checkpoint inhibitors, and discovered that, on average, the efficacy of 
these treatments is surprisingly poor on OC patients (Gaillard et al., 2016). The positive 
outcome was found to be around 10 to 15%. A schematic representation of the 
immunotherapy-based approaches used in OC and the interactions between different 
immune players and tumor cells is provided in Figure 1. 
 
3.1 Monoclonal Antibodies in OC 
In the attempt to enhance treatments for OC, a number of targets involved in tumor 
progression and immune suppression have been used to develop monoclonal antibodies 
capable of inhibiting their functions. Catumaxomab is a monoclonal antibody directed 
against the epithelial cell adhesion molecule (EpCAM), a glycoprotein highly expressed 
in OC (Tayama et al., 2017). This antibody is currently being evaluated in a phase II 
clinical study on patients resistant to chemotherapy (J. S. Berek et al., 2014). Following 
the identification of the Cancer Antigen 125 (CA125), which is the most renowned OC 
marker (Bast et al., 1981), its role as a suppressant of both natural killer cell activity 
(Patankar et al., 2005; Tyler et al., 2012) and antibody-dependent cellular toxicity (Kline 
et al., 2017) has been widely investigated. Several anti-CA125 monoclonal antibodies 
have been developed and tested, including oregovomab (J. Berek et al., 2009) and 
abagovomab (Sabbatini et al., 2013), although they did not prove to be effective in 
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improving the outcomes in advanced OC when used as a single-agent maintenance 
immunotherapy. Anti-CD25, daclizumab, has been clinically tested for its capacity to 
suppress the T regulatory (Treg) cell populations, responsible for shorter patient survival 
rates when infiltrated within the tumor (Barnett et al., 2010). While the trial has been 
completed, the results have not been released yet. The translational potential of anti-
CD25-based platforms is limited by their non-specific binding as CD25 is widely 
expressed on T-cells populations. 
 
3.2 Dendritic cell vaccines in OC 
Dendritic cells have a pivotal role in launching the immune response due to their capacity 
of activating CD4+ or CD8+ T-cells (Sallusto & Lanzavecchia, 2002). Their role in the 
tumor microenvironment is the subject of an active contemporary research (Pfirschke et 
al., 2017). As plastic APC, DC are currently harnessed for their potential to boost the 
immune system against tumor initiation and progression. Scarlett et al. applied an 
inducible p53-dependent model of aggressive ovarian carcinoma to demonstrate that DC 
display differential immunostimulatory capacity during tumor initiation and escape 
(Scarlett et al., 2012). These changes correspond to significantly lower levels of MHC-II 
and CD40 on their surface. DC are tunable cells, capable of inducing either an immune 
surveillance effect or to release malignant growth, by activating or suppressing anti-tumor 
T-cells activity, respectively. DC-based vaccines have also been conceived in the context 
of OC, by ex vivo pulsing DC with tumor-derived components, as single tumor-associated 
peptides or peptide combinations (Liao & Disis, 2013). Cancer testis antigens (CTA) that 
are typically expressed in multiple types of tumors have also gained interest for their 
potential applicability in immunotherapy (Gjerstorff et al., 2015; Seifi-Alan et al., 2018). 
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NY-ESO-1, a member of the CTA family, has been used to produce either DC-based 
vaccines (NCT number NCT02387125) or adoptive T-cell therapies (NCT number 
NCT01567891). Similar immunotherapeutic approaches are being developed using 
melanoma antigens (i.e MAGE-A1, MAGE-A4, MAGE-A3, and MAGE-A10) that 
represent another subgroup of the CTA category (Daudi et al., 2014). Zitvogel et al. are 
among the first researchers to use tumor antigen-pulsed DC to treat mice with 
fibrosarcoma (Zitvogel et al., 1996). They also demonstrated that patient-derived DC 
pulsed with a cocktail of tumor antigens (whole tumor antigen; WTA) can trigger a tumor 
growth suppression through the activation of CD4+ and CD8+ T-cell when reintroduced 
into the patient. In their study, the activation of T-cells correlates with a better prognosis 
in patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer (Kandalaft 
et al., 2013; Tanyi et al., 2018). Recently, a pilot study employing autologous WTA-pulsed 
DC-based vaccine demonstrated to be safe and effective in combination with 
cyclophosphamide and bevacizumab (Tanyi et al., 2018). By priming DC with patient-
derived WTA, Tanyi et al. were able to overcome two of the limitations associated with 
the use of immunotherapy for the treatment of OC, namely the lack of an efficient antigen-
specific active treatment and the inability of tumor-specific T cells to home to tumors.  
 
3.3 Adoptive cell therapy in OC  
Adoptive cell therapies show potential for the treatment of OC. For example, it is shown 
that tumor-infiltrating lymphocytes (TILs) derived from OC biopsies-derived cells can be 
expanded ex vivo and be re-activated to produce anti-tumor cytokines (Owens et al., 
2018). Similarly, the abundance of TILs in patients’ ascitic fluid has prompted their 
evaluation as re-injectable immunotherapies after their demonstrated cytotoxic effect on 
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tumor cells (Abe et al., 2018). CAR-T-based therapy produced by combining 
programmable antigen receptor specificity with T-cell activation also holds an attractive 
opportunity for the treatment of OC (Dzhandzhugazyan et al., 2018). The lack of a 
demonstrable efficacy of this approach is mainly due to the poor T-cell trafficking and the 
immunosuppressive microenvironment (Jindal et al., 2018; Mirzaei et al., 2017; B.-L. 
Zhang et al., 2016). Despite the potential pitfalls of this approach, clinical trials evaluating 
its efficacy on OC are currently active and specifically target mesothelin (NCT 02580747, 
01583686), MUC16 (NCT 02498912), HER2 (NCT 01935843), NY-ESO-1 (NCT 
02366546) among all (X. Zhu et al., 2017).  
 
4. Nanomedicines and Immunotherapy in Ovarian Cancer  
Synthetic and natural nanotechnologies are currently being investigated to deliver 
immunotherapies, as they have the potential to improve patient treatment outcomes and 
reduce the mortality rates (H. Shen et al., 2017). This includes the use of nanoparticles 
for the delivery of immunostimulatory and immunosuppressive molecules in combination 
with chemo- or radiotherapy or as adjuvants to other immunotherapies (Sapiezynski et 
al., 2016). Nanoparticles have  also been designed to produce vaccines to stimulate T 
cell response against tumor growth (Fan & Moon, 2015), allowing for the co-delivery of 
antigen and adjuvants (A. Dunkle et al., 2013), contributing to the inclusion of multiple 
antigens to activate DC targets (Xia et al., 2015), and guaranteeing the sustained release 
of antigens for a prolonged immune stimulation  (Engelberth et al., 2014).  
Literature reports only few examples of pre-clinical studies investigating the potential of 
nanotechnology-based platforms to improve the outcome of immunotherapeutic regimens 
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in OC. These include polymeric nanoparticles (Cubillos-Ruiz et al., 2009; Hanlon et al., 
2011; Ortega et al., 2015; Teo et al., 2015), liposomes (Rajan et al., 2018; Turk, Waters, 
& Low, 2004), and  lipid–polymer hybrids (Anwer et al., 2013).  
Nanoplatforms for OC have been synthesized primarily to guide the delivery of RNA 
oligonucleotides to target cells, thus overcoming the current limitations related to the use 
of RNA therapeutics. Limitations include the low bioavailability, poor cellular uptake, 
cytotoxicity and the need to evade the phagocytic cellular components of the immune 
system (Kole et al., 2012). Polymeric nanostructures have been developed to provide 
additional control over drug release at tumor sites as they offer the advantage of being 
able to respond to specific stimuli provided by the tumor environment, such as pH and 
enzymatic activity (Uthaman, Huh, & Park, 2018). Among the many polymers available, 
polyethylenimine (PEI) is one of the most employed materials in OC treatment as it is 
considered a versatile gene carrier (Teo et al., 2013). PEI displays high efficacy for siRNA 
encapsulation and delivery, for both in vitro and in vivo purposes. Its cationic charge 
enables the loading of siRNA into nanocomplexes and protects it from enzymatic 
degradation (Höbel & Aigner, 2013; M. Zheng et al., 2011). The abundant presence of 
amine groups allows for the functionalization of the platform and favors further 
modifications of this polymer to improve the bioactive features, such as its targeting ability 
and cell specificity. Cubillo et al. have investigated PEI-siRNA nanoparticles uptake by 
tumor-associated DC and its effect in reprogramming their phenotype from 
immunosuppressive cells to efficient APC. The authors found that the changes induced 
in DC through the use of PEI-siRNA against immunosuppressive determinants 
consequently activated tumor-reactive human and murine lymphocytes and exerted a 
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direct tumoricidal activity in aggressive ovarian carcinoma–bearing murine models 
(Cubillos-Ruiz et al., 2009). The induced T cell–mediated tumor regression and prolonged 
survival were dependent upon the activation of the myeloid differentiation primary 
response gene 88 (MyD88). PEI alone was sufficient to mediate the upregulation of MHC-
II, MHC-I and co-stimulatory molecules in tumor DC in vivo. This suggests that the intrinsic 
stimulation of the Toll Like receptors (TLR) 5 and 7 by PEI nanoparticles synergizes with 
the gene-specific silencing activity of the siRNA to transform tumor-infiltrating regulatory 
DC into cells capable of promoting therapeutic antitumor immunity. Cubillos at al. further 
optimized the platform to achieve the synthetic enhancement of the specific molecular 
pathway miR-155 signaling in DC. This pathway is responsible for boosting a potent 
antitumor immune response that abrogates the progression of established ovarian 
cancers (Cubillos-Ruiz et al., 2012). Other researchers have taken advantages of 
polymeric nanoparticles’ capability to be functionalized, thus improving targeting and, 
consequently, the therapeutic outcome. By applying a different immunotherapy-based 
approach Teo PY et al. proposed various folic acid (FA)–functionalized PEI polymers to 
block PD-1/PD-L1 interactions by delivering PD-L1 siRNA to human epithelial ovarian 
cancer (EOC) cells (SKOV-3 line), and to sensitize them against T cells (Teo et al., 2015). 
With their hypothesis to target PD-L1, the authors responded to the need for a specific 
targeted delivery of PD-L1 siRNA to epithelial cancer tissues, as PD-L1 is also expressed 
on healthy tissues (Liang et al., 2003), including placenta and eyes. The polymer/siRNA 
nanocomplexes knocked-down PD-L1 on a luciferase expressing SKOV-3, enhancing the 
efficacy of T cell immunotherapy for the treatment of EOC compared to the respective 
PEI–FA and PEI–PEG–FA/scrambled siRNA treated controls. These data highlight the 
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potential use of PEI–FA as specific gene delivery carriers. The modification of PEI with 
FA or PEG–FA proved to be a valuable tool to reduce cytotoxicity while improving tumor 
cell targeting towards EOC cells and uptake, with a striking ≈40%–50% knockdown of 
PD-L1 expression. Ortega et al. have used click chemistry to produce nanoparticles 
based on 2-(dimethylamino)ethyl methacrylate (DMAEMA) polymer further functionalized 
with the mannose ligand (MnNP). This platform was meant to condense siRNA against 
the polyoma middle T (PyMT) oncogene and specifically target the mannose receptor 
(CD206) present on the surface of TAM (Ortega et al., 2015). MnNP has been 
demonstrated to be biocompatible both in in vitro and in vivo settings. MnNP is also able 
to efficiently incorporate and deliver functional siRNA into the cytoplasm of TAM. This 
study provides evidence that mannosylation is responsible for TAM selectivity in vivo 
following intraperitoneal injection with a 2-fold increase in TAM uptake compared to non-
targeted particles and about 10-fold increase compared to non-myeloid cells. In this study, 
the spatial confinement of the MnNP within the peritoneal cavity enhances the opportunity 
for the interaction with immune cells associated to OC, and the biodegradability of the 
system ensures the persistence of the treatment for over 24 hours.  
Poly(lactic-co-glycolic acid) nanoparticles (PLGA-NP) are biodegradable and their 
composition can be tuned to temporally control the release of the payload (Corradetti et 
al., 2012; Minardi et al., 2016). PLGA-NP have been employed as an alternative route to 
deliver whole WTA to DC since the injection of soluble antigens presents inherent 
limitations due to instability and poor internalization rates. These factors result in the 
transient and inefficient activation of T-cells (Hanlon et al., 2011). At the same time, 
PLGA-NPs protect antigens from enzymatic degradation and maintain their bioactivity, 
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leading to a more efficient presentation of MHC-peptide complexes by recipient cells 
following uptake and processing. In vitro studies confirmed the effectiveness of PLGA-
NPs in the activation of a CD8+ cell response, characterized by a significant increase in 
the production of inflammatory cytokines, a greater expression of co-stimulatory 
molecules, and providing encouraging evidence for their potential clinical translation. 
Interestingly, the delivery of WTA through PLGA-NP appeared to facilitate the antigens 
access to the MHC class I compartment in the cytoplasm, providing a reservoir for a 
prolonged and enhanced Ag presentation.  
Liposomes are small artificial spherical vesicles synthesized primarily from natural non-
toxic phospholipids (Akbarzadeh et al., 2013). Their wide application as drug-delivery 
systems in biomedical settings is due to their biocompatibility, biodegradability, low 
toxicity, and capability to load both hydrophobic and hydrophilic drugs (Johnston et al., 
2007). Moreover, liposomal encapsulation offers the advantage to effectively enhance the 
solubility of lipophilic and amphiphilic drugs, and to improve site-specific drug delivery to 
tumor tissues through surface functionalization (Corradetti et al., 2012; Hofheinz et al., 
2005). The latter aspect is crucial to increase the retention time which can be modulated 
by drug-lipid interactions, and permit the accumulation of liposome-encapsulated 
chemotherapeutic agents at the tumor site (Deshpande et al., 2013).  
Doxil is the first pegylated liposome-based drug to enter the market in 1995. The 
nanoformulation includes doxorubicin, a DNA intercalating agent used against a variety 
of cancers, including gynecological cancers (Howard, et al., 2016). While no significant 
differences were observed in terms of efficacy compared to the free drug, the liposomal 
formulation allowed to reduce cardiotoxicities related to the use of doxorubicin and to 
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preferentially accumulate the drug at the tumor site (Green & Rose, 2006). More recently, 
the FDA approved the use of RNAi-therapeutic delivered by lipid nanoparticles, the 
patisiran (D. Adams et al., 2018). While developed for the treatment of degenerative 
diseases, Patisiran shows promise as a new breakthrough in patient care as it heralds 
the arrival of an entirely new class of medicines to treat human diseases. Despite the 
wide interest in the use of liposomal formulations for OC treatment, however, only one 
group has tested liposomes as nanocarriers for immunotherapy. Turk et al. developed 
folate-conjugated liposomes to target intraperitoneal ovarian carcinoma cells as they 
overexpress the folate receptor (Turk et al., 2004). Data revealed that this formulation 
was also uptaken by TAM through a folate receptor-mediated internalization, with a 10-
fold increase in the engulfment of macrophages compared to ascitic tumor cells in vivo, 
corroborating the need to develop combinatorial strategies aiming at modulating TAM and 
inhibiting cancer cells growth.  
 
Lipid–polymer hybrid nanoparticles (LPN) are core–shell nanoparticle structures 
constituted by a polymeric core and a lipid shell. LPN have been considered by other 
researchers to confer a high degree of physical stability to the platform, resulting in a 
superior in vivo cellular delivery efficacy (Hadinoto et al., 2013) compared to polymeric 
and liposomal nanoparticles. The combination of the two LPN platforms formulated with 
a lipopolymer PEG-PEI-Cholesterol were employed as an effective tool to deliver an 
interleukin 12 (IL-12) plasmid at the tumor site. IL-12 was chosen for the therapeutic 
action it plays in OC, which relies on its potential to activate the anti-tumor immunity 
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(Whitworth & Alvarez, 2011). This approach proved to be safe and effective in platinum-
sensitive OC patients treated with IV carboplatin and docetaxel (Anwer et al., 2013).  
 
5. Physical and biological barriers challenging the treatment of OC 
Innovative immunotherapeutic targeted strategies mediated by nanotechnology offer the 
promise of enhancing host anti-tumor responses which may improve clinical outcomes in 
women with OC. Although preclinical studies have demonstrated the induction of an anti-
tumor response, there is no clinically effective nanomedicine-based immunotherapy 
available for OC patients. The biological barriers that physically and mechanically 
influence the processes involved in tumor spread and immune cell infiltration must be 
considered when developing new strategies for the treatment of OC. As mentioned 
above, one of the main mechanisms by which OC cells spread is through transcoelomic 
metastasis, which involves dissemination throughout the peritoneal cavity (Tan, Agarwal, 
& Kaye, 2006). Ascites formation is determined by the accumulation of cancer cells, 
growth factors and immunosuppressive ligands (VEGF and fibroblastic growth factor beta 
(FGF-b)), which increase peritoneal capillary permeability (Ahmed & Stenvers, 2013) and 
thus the leakage of plasma proteins (i.e albumin, fibrin and fibrinogen) from newly 
developed vessels (Stanojevic et al., 2004). The obstruction of lymphatic vessels by 
cancer cells also occurs, which leads to an impaired re-absorption of the physiological 
peritoneal fluid (Kipps et al., 2013). As a consequence of the compromised lymphatic 
drainage of the peritoneal cavity, fluid confinement in the peritoneum occurs contributing 
to the pathogenesis of malignant ascites. The environment that these biological and 
physical processes create impedes immune cell migration and infiltration within the 
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metastatic tumors (Cai & Jin, 2017), and induces a peripheral tolerance that attenuates 
their function (Kulshrestha et al., 2017). For instance, ascites proved to recruit and 
immunologically suppress a population of neutrophils through cell contact in a cohort of 
newly diagnosed OC patients (Singel et al., 2017). The release of macrophage migration 
inhibitory factor (MIF) from ascites-derived cancer cells has also been  proposed to halt 
the tumour-killing ability of NK cells by transcriptionally down regulating the expression of 
the surface receptor NKG2D (Krockenberger et al., 2008). These findings confirm the 
proactive role of malignant ascitic fluid in physically supplying cells and chemical stimuli 
to favour an immune suppressed environment. Additionally, another physical barrier to 
immune cells penetration is represented by the tumour vascular endothelium (Motz & 
Coukos, 2013). In a physiological environment the presence of adhesion molecules such 
as intercellular cell adhesion molecule (ICAM) or vascular cell adhesion molecule (VCAM) 
allows T-cells to adhere to and travel through the endothelium. In the tumour milieu the 
release of angiogenic growth factors impedes T-cell to pass through by inhibiting the 
adhesion molecules expression (Bouzin et al., 2007).  
The employment of nano-sized molecules/structures able not only to precisely target and 
accumulate at the site of interest, maintain the bioactivity of the drug while ensuring its 
release but also to overcome biological and physical barriers is pivotal in unveiling the 
mechanisms behind tumoral immune suppression. The development of approaches 
capable of capitalizing on the transport oncophysics of the peritoneal cavity will improve 
the delivery strategies for the treatment of metastatic OC (Nizzero et al., 2018).  
 
6. Exosomes: an alternative tunable and nanoscopic strategy 
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Recently, biological nanoparticles (called exosomes) have also emerged as a powerful 
translational platform to be harnessed in the development of naturally inspired delivery 
systems. Exosomes are nanoscopic lipidic vesicles with a size range spanning from 30 
to 150 nm that are released by cells and thus retain their bioactive moieties. Due to their 
small size and architecture exosomes can penetrate across the lymphatic vessels and 
tumor interstitium and reach target organs (S. Srinivasan et al., 2016). Their composition 
and cargo can be further modified by conditioning parental cells or by improving their 
natural potential with the addition of functional drugs, thus conferring them additional 
functions (Conlan et al., 2017). Exosomes play a crucial role in cell-to-cell communication 
and are characterized by a precise targeting potential that allows for the activation or 
repression of specific molecular cascades in targeted cells (Syn et al., 2017). Currently, 
their role in the exchange of information between the tumor and the surrounding 
microenvironment is being explored (Maia et al., 2018), as is their potential as delivery 
vessels for both therapeutic and imaging purposes (Luan et al., 2017; L.-M. Shen et al., 
2018).  
Recent advances in the field of immunotherapy unveiled the role of appropriately 
stimulated exosomes released from cancer cells as potent endogenous nanocarriers 
responsible for the suppression of T cells and the facilitation of tumor growth (Chen et al., 
2018). Once injected for therapeutic purposes, exosomes are not susceptible to further 
modifications determined by the microenvironment, offering a great advantage over the 
use of CAR-T cells or DC, which are amenable to acquire a different phenotype 
(Yamashita et al., 2018). 
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Interestingly, they have been also proposed as useful tools to predict the patient response 
to immunotherapy. On the other hand, exosomes derived from immune cells, APC or 
TAM, are now at the forefront for the development of innovative vaccine strategies for 
cancer immunotherapy against tumor initiation and are the subject of current clinical trials 
for the treatment of other tumor types (Hong et al., 2017; Liu et al., 2018).  
 
7. Conclusions and Perspectives 
In this review we have discussed the widely recognized impact of immunotherapy in the 
treatment of cancers, highlighting the challenges researchers face in the effort to 
overcome the limitations provided by OC. These include its cold nature, determined by 
the immunosuppressive environment and the transport oncophysics, which urgently calls 
for the conception of alternative approaches to deliver immunotherapies. Ideally, these 
approaches are meant to preferentially accumulate the drug at the tumor site, sustain the 
temporal and spatial release of the payload thereby reducing cytotoxicity, and selectively 
target specific cell types to stimulate anti-tumor immunity (Figure 2). Nanotechnology 
offers advantageous drug delivery systems with demonstrated therapeutic efficacy, with 
a direct or indirect effect on cancer cells. However, the potential of nanomedicines for the 
treatment of OC has been limitedly harnessed. Although capable of identifying and 
targeting the cell population of interest, none of the nano-enabled strategies proposed 
have yet shown significant clinical benefits. Furthermore, literature lacks a comprehensive 
discussion about the in vivo biodistribution of the proposed nanoplatforms, reinforcing the 
concept that the drastic changes within the peritoneal cavity in terms of transport 
oncophysics and metastases heterogeneity, largely limit their capability to reach tumor 
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masses. A deep understanding of the role exosomes play in travelling and mediating cell 
interaction within the OC environment will successfully lead to the development of cutting-
edge approaches to prime the body’s immune system against tumor initiation. The 
continuous advancements in the field of nanotechnology will provide the tools needed to 
synthesize exosomes-resembling particles to be used as alternative immunotherapy 
treatment for OC. Another approach may include the coupling of naturally derived 
exosomes with established multistage vectors (MSV), demonstrated to achieve efficient 
delivery of chemotherapeutics to metastatic breast cancer (Xu et al., 2016) and ovarian 
tumor tissues (H. Shen et al., 2013). The possibility to exploit the physical properties of 
the ascitic fluid and the geometry of the peritoneal cavity during metastatic OC to tailor 
the architecture of MSV paves the way for the fabrication of nanotechnology-based 
immunotherapies to accomplish the challenge of boosting the anti-cancer immune system 
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Figure 1. Schematic of the current immunotherapies for Ovarian Cancer. Arrows show 
the interactions between immune system players (Dendritic Cell, T cells, Macrophages, 
and Monoclonal antibodies) and ovarian cancer cells. Each specific immune cell type can 
be employed to deliver specific therapies that can differently alter the immune system 
towards a more efficient activity rate. 
 
Figure 2. Schematic representation of intraperitoneal injection (IP) of nanoparticles (NP) 
able to follow the ascetic fluid movement (green arrows) and reach metastatic sites. 
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Table 1. List of current therapies for Ovarian cancer. Chemotherapies and targeted 
therapies are FDA approved. Some of the nanotherapies mentioned are already used in 
clinics, but the majority of them is still undergoing clinical trials. 
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Gold standard chemotherapeutic 
Drug name Drug class FDA 
approved 
Reference 
Doxorubicin Antibiotics/antineoplastics 1995 (Bolis et al., 
1978) 
Carboplatin Alkylating agents 1989 (M. Adams 
et al., 1989) 
Paclitaxel Mitotic inhibitors 1998 (Khanna et 
al., 2015) 
Cyclophosphamide Alkylating agents 1959 (Handolias 
et al., 2016) 
Gemcitabine Antimetabolites 2006 (Lorusso et 
al., 2006) 
Melphalan Alkylating agents 2001 (Hasan & 
Jayson, 
2003) 
Cisplatin Alkylating agents 1978 (Monneret, 
2011) 
Topotecan Miscellaneous antineoplastics 1996 (Seiden et 
al., 2004) 
Etoposide Mitotic inhibitors 1998 (Long et al., 
2005) 








Bevacizumab VEGF/VEGFR inhibitors 2004 (Rossi et al., 
2017) 
Olaparib PARP inhibitors 2017 (Moore et 
al., 2018) 
Niraparib PARP inhibitors 2017 (Essel & 
Moore, 
2018) 
Rucaparib PARP inhibitors 2018 (Dal Molin et 
al., 2018) 
 
Current nanotechnology treatments and ongoing trials 












1999 (Pisano et 
al., 2013) 
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Table 2. FDA-approved immunotherapeutics since the beginning of 2018. 






Stage III non-small cell lung 
cancer  
Feb 16, 2018 
Brentuximab vedotin 
(Adcetris, Seattle Genetics, 
Inc.) 
antibody-drug conjugate 
targeting the CD30 receptor 
Untreated classical Hodgkin 
lymphoma  
Mar 20, 2018 
Blinatumomab (Blincyto, 
Amgen Inc.) 
bispecific T cell-engaging 
antibody targeting CD19 
receptor 
B-cll precursor acute 
lymphoblastic leukemia  
Mar 29, 2018 
Nivolumab (Opdivo, Bristol-




targeting PD-1 and CTLA-4  
Advanced renal cell carcinoma Apr 16, 2018 
Tisagenlecleucel (Kymriah, 
Novartis) 
CAR T cell immunotherapy 
targeting CD19 receptor 
Relapsed / refractory large B cell 
lymphoma 




targeting PD-1  




targeting anti-PD-1  
Adult and pediatric primary 
mediastinal large B-cell 
lymphoma 
Jun 13, 2018 
Nivolumab (Opdivo,l Bristol-




targeting PD-1 and CTLA-4  
Relapsed colorectal cancer with 
high microsatellite instability or 
deficient DNA mismatch repair 






2012 (Chou et al., 
2006) 
Genexol-PM Mitotic inhibitors PEG-PLA 
polymeric micellar 
Paclitaxel 
Phase II (Lee et al., 
2017) 
LEP-ETU Mitotic inhibitors Liposomal 
Paclitaxel 
Phase I (Damjanov 
et al., 2005) 
Paclical Mitotic inhibitors Paclitaxel micelles Phase III NCT009891
31 
OSI-211 Antineoplastics Liposomal 
Lurtotecan 
Phase II (Seiden et 
al., 2004) 
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targeting PD-1  
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